Intermediate Syndrome Following Organophosphate Insecticide Poisoning in Emergency Department of Eastern Nepal

Ritesh Chaudhary¹, Rabin Bhandari², Gyanendra Malla³, Masum Poudel⁴

¹Department of General Practice and Emergency Medicine, B. P Koirala Institute of Health Sciences, Dharan, Nepal

ABSTRACT:
Acute organophosphate poisoning is the most common pesticide poisoning which can be manifested in three unique phases of toxic effects e.g. Acute Cholinergic Crisis, Intermediate Syndrome (IMS), Delayed Polyneuropathy. The present study attempted to report a comparable form of incidences encountered in Emergency Department of BP Koirala Institute of Health Sciences (BPKIHS) in Eastern Nepal. Chloryprphos was the commonest compound associated with IMS. Early recognition with plasma acetylcholinesterase level as well as Peradeniya Organophosphorus Poisoning (POP) Scaled score might be useful tool in early diagnosis of Intermediate Syndrome.

Key words: Acute Organophosphate Poisoning, Eastern Nepal, Intermediate Syndrome.

1. Introduction:
Acute organophosphate poisoning is most common poisoning and accounts nearly 3 million cases every year resulting deaths in more than 250,000. It is a major health problem worldwide and important clinical emergency and contributor to morbidity and mortality. [1]

It can manifest in three different phases of toxic effect e.g. Acute Cholinergic Crisis, Intermediate Syndrome (IMS) and Delayed Polyneuropathy. Acute cholinergic crisis develops within a few minutes to several hours after exposure, and affects peripheral muscarinic and nicotinic receptors, as well as the central nervous system, through the inhibition of carboxylic esterase enzymes. Organophosphate- induced delayed neurotoxicity (OPIDN) occurs 2–3 weeks after acute exposure to certain organophosphate insecticides. The clinical features are predominantly motor neuropathy and primarily manifest as numbness and weakness of the lower extremities, followed by progressive ascending weakness of limb muscles. The disease entity is believed to be due to the inhibition of a poorly characterized esterase called the neuropathy target esterase. [2-5]

In between the interval of acute cholinergic crisis and OPIDN, organophosphate compound can cause IMS which was first described by Senanayake et.al.1987. It is mainly characterized by weakness of proximal limb muscles, neck flexors, respiratory muscles, and motor cranial nerves, and was attributed to muscle fiber necrosis following acute cholinergic crisis. Following previous case studies the incidence of Intermediate syndrome has been reported to be as high as 80%. [6-12]

The present study tried to report a case series of the manifestations of Intermediate Syndrome following Acute Organophosphate Poisoning in Emergency Department eastern Nepal.

2. Illustrative case:

Case 1
A 17-year old married female was referred from a local hospital to Emergency Department of BP Koirala Institute of Health Sciences (BPKIHS) with alleged history of ingestion of Chloryprphos 40% with suicidal intent week ago with complaints of inability to sit and unable to hold neck since 1 day. On examination her Glasgow Coma Scale (GCS) was E4 M6 V3, Blood Pressure: 110/60 mm Hg, Heart Rate: 92/min, Respiratory Rate: 24/m, SpO2: 97% at room air. Pupils were less than 2 mm size with Peradeniya Organophosphorus Poisoning (POP) Scaled as moderate poisoning. Her neck muscles weakness was first manifestation followed by proximal muscles weakness of upper and lower limbs. Her Urea was 17, Creatinine: 03 mg/dl, Total count: 11400 mg/dl, PT/INR: 14/1, SGPT: 14 U/L, SGOT: 15 U/L, GGT: 30 U/L. Her serum acetyl cholinesterase level at index visit was 165 < 2 mm size with Peradeniya Organophosphorus Poisoning (POP) Scaled as moderate poisoning. Her neck muscles weakness was first manifestation followed by proximal muscles weakness of upper and lower limbs. Her Urea was 17, Creatinine: 03 mg/dl, Total count: 11400 mg/dl, PT/INR: 14/1, SGPT: 14 U/L, SGOT: 15 U/L, GGT: 30 U/L. Her serum acetyl cholinesterase level at index visit was 165 U/L. ABG and Urine routine examination revealed within normal limits. The patient was transferred to Intensive Care Unit (ICU) and was managed conservatively with intravenous fluids, Pralidoxime and Atropine. The patient condition improved in ICU and was discharged on 7th day with normal regain of power of neck and limb muscles.

Case 2
A 41 year- old lady was brought by her spouse with alleged history of ingestion of organophosphate compound (Chloryprphos 50% and Cypermethrin 5%) ten days prior to admission. She was managed at local hospital and then was referred to Emergency Department of BP Koirala Institute of Health Sciences (BPKIHS) for further management. She had history of vomiting multiple episodes, abnormal body movements and dizziness at the index visit. On examination her Glasgow Coma Scale (GCS) was E2 M3 V3, Blood Pressure: 150/80 mm Hg, Heart Rate: 105/min, Respiratory Rate: 28/m, SpO2: 89% at room air. Pupils were less than 2
mm size with Peradeniya Organophosphorus Poisoning (POP) Scaled as moderate poisoning. Weakness was noticed in proximal muscles of upper and lower limbs. Her Urea was 10, Creatinine: 1.2 mg/dl, Total count: 24200 mg/dl, PT/INR: 14/1, SGPT: 39 U/L, SGOT: 29 U/L, GGT: 12 U/L, Lipase 149 U/L and Amylase was 232 U/L. Her serum acetyl cholinesterase level was 139 U/L. On ABG (Arterial Blood Gas) her P\textsubscript{O}_2 was 7.44, P\textsubscript{CO}_2 32.1, PO\textsubscript{2} 80.5, Lactate 1.0 and HCO\textsubscript{3}	extsuperscript{-} was 21.8. Urine routine examination and ECG revealed within normal limits. The patient was managed meticulously as per protocol with intravenous fluids, atropine and pralidoxime and Benzo-diazepines. Airway was secured by artificial ventilation. Despite intensive respiratory and ventilator support the patient was expired on the 3\textsuperscript{rd} day.

3. Discussion:

Intermediate syndrome is a major cause of morbidity and mortality in patients with acute organophosphate insecticide poisoning. It is well recognized as a disorder of neuromuscular junctions but its exact etiology, incidence, and risk factors are not clearly defined because a previous study are largely small-scale case series and was irrelevant for a consistent and rigorous definition of IMS. [13]

IMS has been commonly associated with organophosphate compounds like diazinon, dimethoate, methylparathion, methamidaphos, monocrotophos, fenithion and ethylparathion which are quite different in our study that is chlopyriphos. [14, 19]

In one study done by Aygun D et. al. 2002 found that the level of plasma acetylcholinesterase level poorly correlated in IMS. [15] There may be a considerable variations between the methods used for estimation of IMS and plasma acetylcholinesterase level to detect its toxicity. [16] Therefore, serial estimations of plasma acetylcholinesterase may be more useful in diagnosis of Intermediate Syndrome.

Involvement of Cranial nerve palsy as reported from Sri Lanka and the involvement of proximal muscles in other studies were quite similar to our study. The chance of survival in IMS is very controversial that what we found in our case study but in most of the studies in literatures found that mortality varied from 10.5% to 41.6%. [2, 17-18]

From the study done by Vikram et. al. 2005 the time taken for recovery from the manifestations varied from 3-12 days [19] which was quite consistent with our case report who completely recovered and discharged uneventfully on 7th day. On the other side even after institution of intensive respiratory and ventilator support along with Cardiopulmonary resuscitation the patient didn’t recovered which might explain delayed recognition leading to respiratory failure.

4. Conclusion:

From these case series we conclude that early recognition and supportive therapy remains the cornerstone for the management of the patient with Intermediate Syndrome. In a view of high mortality plasma acetylcholinesterase level as well as POP score might be useful tool in early diagnosis of Intermediate Syndrome.

The appropriate treatment protocol should be established in every Emergency Department and Intensive care units of district and private hospitals in Nepal.

References:


[19] Dr. VikramPalimar, Dr Arun M, Dr Mohan Kumar T. S. Dr K. M. Saralaya. Intermediate syndrome in organophosphorous poisoning. JIAFM, 2005: 27 (1). ISSN 0971-0973